Planet MicroCap spoke with Rene Goehrum, President, CEO and Chairman of BioSyent Inc. (TSX-V: RX) via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

[0:50] Quick overview of BioSyent Inc.
[2:04] Highlights from the last 6-7 months (since September 2023): 2023 financial performance, launch of Gelclair
[4:10] Goals for 2024

For more information about BioSyent Inc., please visit: [ Ссылка ]

BioSyent Inc. will be presenting at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024. Register to participate here: [ Ссылка ]

The interview may contain forward looking statements about BioSyent Inc. See BioSyent Inc.'s periodic filings with SEDAR for more complete information.

About BioSyent Inc.

Listed on the TSX Venture Exchange (TSXV: RX), BioSyent is a profitable growth oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units.

Subscribe NOW to Planet MicroCap: [ Ссылка ]

Get more Planet MicroCap:
Website: [ Ссылка ]
Follow Planet MicroCap: [ Ссылка ]
Like Planet MicroCap: [ Ссылка ]
Follow Planet MicroCap on LinkedIn: [ Ссылка ]...

Planet MicroCap is the Official YouTube Channel for the MicroCap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!

свернуть